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SerpinB3 Promotes Pro-fibrogenic 
Responses in Activated Hepatic 
Stellate Cells
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Chiara Busletta1, Alessandra Biasiolo2, Santina Quarta2, Elisabetta Morello1, Claudia Bocca1, 
Antonella Miglietta1, Ezio David4, Salvatore Sutti5, Mario Plebani2, Emanuele Albano5, 
Maurizio Parola1 & Patrizia Pontisso2
SerpinB3 is a hypoxia- and hypoxia-inducible factor-2α-dependent cystein protease inhibitor that 
is up-regulated in hepatocellular carcinoma and in parenchymal cells during chronic liver diseases 
(CLD). SerpinB3 up-regulation in CLD patients has been reported to correlate with the extent of liver 
fibrosis and the production of transforming growth factor-β1, but the actual role of SerpinB3 in hepatic 
fibrogenesis is still poorly characterized. In the present study we analyzed the pro-fibrogenic action 
of SerpinB3 in cell cultures and in two different murine models of liver fibrosis. “In vitro” experiments 
revealed that SerpinB3 addition to either primary cultures of human activated myofibroblast-
like hepatic stellate cells (HSC/MFs) or human stellate cell line (LX2 cells) strongly up-regulated 
the expression of genes involved in fibrogenesis and promoted oriented migration, but not cell 
proliferation. Chronic liver injury by CCl4 administration or by feeding a methionine/choline deficient 
diet to transgenic mice over-expressing human SerpinB3 in hepatocytes confirmed that SerpinB3 over-
expression significantly increased the mRNA levels of pro-fibrogenic genes, collagen deposition and 
αSMA-positive HSC/MFs as compared to wild-type mice, without affecting parenchymal damage. The 
present study provides for the first time evidence that hepatocyte release of SerpinB3 during CLD can 
contribute to liver fibrogenesis by acting on HSC/MFs.
Liver fibrogenesis is a dynamic and highly integrated process that, irrespective of the etiology, results in a progres-
sive accumulation of extracellular matrix (ECM) components and drives the progression of chronic liver disease 
(CLD)1–3. A major pro-fibrogenic role is played by hepatic myofibroblasts (MFs)1–9 which mainly originate from a 
process of activation/trans-differentiation of hepatic stellate cells (HSC) or HSC/MFs8, 9. The persistent activation 
of these cells is the consequence of a complex interaction between growth factors, cytokines, chemokines, reac-
tive oxygen species (ROS) and other mediators1–7. In the pro-fibrogenic environment these factors are released 
by- and interact with- several liver cell populations, including damaged hepatocytes, activated inflammatory 
cells and MFs1–7. Accordingly, the identification and characterization of the mediators involved in sustaining the 
pro-fibrogenic role of MFs during CLD progression is a critical issue to design novel selective therapeutic strate-
gies and/or to develop diagnostic procedures.
Along these lines, SerpinB3, a member of the family of serine-proteases inhibitors (serpins)10, 11, has recently 
emerged as a mediator involved in CLD progression12, 13 and in liver carcinogenesis14–18. SerpinB3 expression is 
regulated by hypoxia through the hypoxia-inducible factor-2α (HIF-2α)19. In normal human and murine livers 
SerpinB3 is virtually undetectable, but its expression is readily appreciable in a significant percentage of liver 
biopsies from CLD patients, as well as in hepatocellular carcinoma (HCC)12–18 and hepatoblastomas20. In both 
neoplastic and non-neoplastic settings, liver SerpinB3 up-regulation correlates with that of transforming growth 
factor-β1 (TGF-β1), a critical mediator in liver fibrogenesis12, 21. In particular, a study performed in liver biopsies 
from 94 patients with CLD of different etiology has outlined a significant “in vivo” correlation between TGF-β1 
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and SerpinB3 expression (protein and mRNA level). The same study also reported “in vitro” data showing that 
SerpinB3 over-expression in hepatocyte-derived cells also promoted TGF-β1 release, suggesting that SerpinB3 
may contribute to up-regulate TGF-β1 production during chronic injury12. The putative pro-fibrogenic action 
of SerpinB3 has also been evidenced in human idiopathic pulmonary fibrosis22 and in a murine model of lung 
fibrosis23, 24. Nonetheless, the mechanisms by which SerpinB3 may contribute to liver fibrogenesis are still poorly 
characterized.
In the present study we investigated the putative pro-fibrogenic role of SerpinB3 first by performing experi-
ments “in vitro” using human HSC/MFs and then “in vivo” taking advantage of two different experimental pro-
tocols of chronic liver injury in transgenic mice overexpressing human SerpinB3 in hepatocytes (TG-SB3 mice).
Results
SerpinB3 up-regulates transcription of key pro-fibrogenic genes in human HSC/MFs. The 
addition of human recombinant SerpinB3 (hrSerpinB3) to cultures of human immortalized activated MF-like 
cells (LX2 cells) resulted in the up-regulation of the transcripts for key pro-fibrogenic genes, including TGFβ1 
(TGFB1), COL1A1, α-SMA, platelet-derived growth factor (PDGF)-B and the related PDGF-β receptor 
(PDGFBR) subunit, TIMP-1, MMP-1 as well as C-C motif chemokine ligand 2 (CCL2) (Fig. 1a). The activa-
tion of these genes was also fully reproduced in primary cultures of human HSC/MFs exposed to hrSerpinB3 
(Supplementary Fig. 1a). Furthermore, upon hrSerpinB3 addition, both LX2 cells and primary culture of human 
HSC/MFs up-regulated the transcription of pro-angiogenic cytokines relevant in sustaining liver fibrogenesis25, 
26 such as VEGF-A (VEGFA) and Angiopoietin-1 (Ang-1 or ANGPT1) (Fig. 1b; Supplementary Fig. 2). In HSC/
MFs SerpinB3 also stimulated the expression of TIE-2, the gene encoding for the Ang-1 receptor (Supplementary 
Fig. 2). Interestingly, already 6 hours after hrSerpinB3 addition LX2 cells released VEGF-A protein in the extra-
cellular medium and this effect reached a maximum in the following 24–48 hours (Fig. 1c,d).
Figure 1. SerpinB3 up-regulates expression of genes involved in liver fibrogenesis in immortalized human HSC 
(LX2 cells). (a) Analysis by quantitative real-time PCR (Q-PCR) of transcript levels of pro-fibrogenic genes, 
of CCL2 as well as of (b) VEGF-A or angiopoietin 1 (Ang-1) in human LX2 cells exposed for the indicated 
time points to 100 ng/ml human recombinant SerpinB3 (SB3). Data are expressed as means ± SEM of three 
independent experiments (*p < 0.05 or **p < 0.01 vs control values). (c,d) WB Analysis of VEGF-A protein in 
total extracts (left panel) and immuno-precipitated VEGF-A protein levels released in the extracellular medium 
collected at the indicated time points. The cropped gels shows in this Fig. have been run under the same 
experimental conditions.
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SerpinB3 induces oriented migration in human HSC/MFs. We next evaluated whether SerpinB3 may 
modulate proliferation and chemotaxis of activated HSCs. Human LX2 cells as well as human primary HSC/MFs, 
which responded positively to the potent mitogen and chemoattractant PDGF-BB (used as positive control), 
failed to show appreciable increase in proliferation when exposed to hrSerpinB3 (Fig. 2a,b). However, both LX2 
cells (Fig. 2c) and human HSC/MFs (Fig. 2d) showed oriented migration when exposed to hrSerpinB3 in a modi-
fied Boyden’s chamber assay. Additional experiments, designed to investigate the chemoattractant action, revealed 
that LX2 cells exposed to hrSerpinB3 had features in common with those induced by other chemo-attractants 
on activated HSCs27. This included very early activation/phosphorylation of c-Jun NH2-terminal kinase isoforms 
−1 and −2 (JNK1/2) and c-Akt, with no relevant change in activation/phosphorylation of extracellular-regulated 
kinase isoforms 1 and 2 (ERK1/2) (Fig. 2e). In addition, hrSerpinB3 also promoted HSC/MF generation of 
intracellular ROS that was evident already after 15 min (Fig. 3b). As previously shown for other chemoattract-
ants27, hrSerpinB3-induced oriented migration was almost abolished by pre-treating HSC/MFs with pharma-
cological inhibitors of either NADPH-oxidase (apocynin, Diphenyleneiodonium or DPI) or of JNK1/2 and 
c-Akt (SP600125 or LY294002) (Fig. 3c). Furthermore, apocynin-mediated inhibition of ROS generation by 
NADPH-oxidase also blocked the activation/phosphorylation of JNK1/2 but not that of c-Akt (Fig. 3d), confirm-
ing that the chemotactic action of SerpinB3 mainly involves the same ROS- and JNK1/2-related signals described 
for other chemoattractants like PDGF-BB, VEGF-A and CCL2 that are active on HSC/MFs27.
Transgenic mice over-expressing human SerpinB3 in murine hepatocytes develop more liver 
fibrosis than wild type littermates. As mentioned above, SerpinB3 is virtually undetectable in either 
human or murine livers, but it is produced in response to liver hypoxia by hepatocytes or hepatic cancer cells in 
a significant fraction of patients with cirrhosis or hepatocellular carcinoma19. In order to mechanistically inves-
tigate whether SerpinB3 may operate as a pro-fibrogenic mediator we employed previously characterized trans-
genic mice that overexpress human SerpinB3 (TG-SB3 mice) in hepatocytes and in lung epithelial cells24. The 
livers of naïve SerpinB3 TG-mice had normal morphology and hepatocytes of naïve SerpinB3 TG-mice as well 
as of related wild type mice did not differ for the expression of albumin, cytokeratin 18, α-fetoprotein or the 
Figure 2. hrSerpinB3 stimulates oriented migration, but not proliferation, in human LX2 cells and human 
HSC/MFs. (a,b) Confluent and 24 hr starved LX2 cells (a) or HSC/MFs (b) were left untreated or exposed to 
either hrSerpinB3 (100 ng/ml) or PDGF-BB (10 ng/ml, positive control) for further 48 hrs and then evaluated 
for proliferation using the crystal violet assay (see Methods). (c,d) Analysis of oriented migration in the 
modified Boyden’s chamber assay of LX2 cells (c) or HSC/MFs (d) exposed or not to either hrSerpinB3 (100 
ng/ml) or PDGF-BB (10 ng/ml, positive control). Data in bar graphs are expressed as means ± SEM of three 
independent experiments (**p < 0.01 vs control values). (e) Western blot analysis of activation of ERK1/2, 
JNK1/2 and Akt signaling pathways in LX2 cells exposed to hrSerpinB3 (100 ng/ml). Confluent and 24 hr 
starved LX2 cells were exposed to SerpinB3 for the indicated time points and activation of pathways was 
evaluated in total extracts by analysis of levels of phosphorylated versus un-phosphorylated levels of ERK1/2, 
JNK1/2 and c-Akt. The cropped gels shows in this Fig. have been run under the same experimental conditions.
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ability to store glycogen and were all negative for cytokeratin 7 expression (Supplementary Figure 3). SerpinB3 
expression was evident in parenchymal cells (Fig. 4a) and Western blot analysis confirmed the exclusive pres-
ence of human SerpinB3 in TG animals (Fig. 4b). This pattern corresponded to that seen in CLD patients where 
SerpinB3 immunostaining was mainly detectable in hepatocytes (Fig. 4c). In human specimens from HCV cir-
rhotic patients (METAVIR F4) SerpinB3-positive cells were usually detectable in hypoxic areas, as shown by the 
concomitant expression of HIF2α and VEGF-A (Fig. 4d).
For evaluating the actual impact of SerpinB3 on the evolution of hepatic fibrosis TG-SB3 mice and corre-
sponding WT littermates were exposed to chronic liver injury. To this aim we used two different experimen-
tal murine models: (i) chronic CCl4 administration, which results in post-necrotic bridging fibrosis resembling 
pan-lobular/parenchymal fibrosis found in the clinical conditions in which SerpinB3 expression has been best 
characterized2, 28, 29; (ii) mice fed with the MCD diet, that leads to pericellular/perisinusoidal fibrosis similar 
to that seen in human NAFLD/NASH2, 28, 29. Naive TG-SB3 mice had plasma SerpinB3 levels around 2 ng/mL 
(1.8 ± 0.6 ng/mL) that were enhanced by 5–10 fold in response to chronic liver injury. In particular, CCl4-treated 
animals showed circulating SerpinB3 twice as higher than those receiving the MCD diet (21.5 ± 6.7 ng/mL vs 
10.5 ± 5.4 ng/mL; p < 0.001). In the transgenic animals SerpinB3 over-production did not influence hepatocellu-
lar damage, as liver histology and the circulating levels of alanine (ALT) and aspartate (AST) aminotransferases 
were comparable to those in wild type mice (Fig. 5). On the other hand, TG-SB3 mice receiving CCl4 or the 
MCD diet showed a higher hepatic expression of inflammatory markers TNF-α and CD11b (Fig. 5) than the 
relative wild type animals. In both models of chronic liver injury, collagen Sirius Red staining revealed that the 
overexpression of SerpinB3 resulted in a marked increase in the extension of fibrosis. In a similar manner the 
number of α-SMA positive HSC/MFs was significantly higher in TG-SB3 mice exposed to CCl4 or the MCD 
Figure 3. hrSerpinB3-dependent induction of oriented migration relies on intracellular generation of ROS and 
specific signaling pathways. (a,b) Confluent and 24 hr starved LX2 cells were left untreated or exposed to either 
hrSerpinB3 (100 ng/ml) or PDGF-BB (10 ng/ml, positive control) and then evaluated for early (i.e., 15 minutes) 
intracellular generation of ROS as shown by DCFH-DA fluorescence (a) or flow cytometry analysis (b). (c,d) 
Analysis of oriented migration in the modified Boyden’s chamber assay (c) or Western blot analysis of activation 
of JNK1/2 and Akt signaling pathways (d) of control LX2 cells or LX2 cells exposed to hrSerpinB3 (100 ng/
ml) in the presence of pharmacological inhibitors of JNK1/2 (SP, SP600125,) and Akt (LY, LY294002) or in the 
presence of apocynin (APO) or diphenylen-iodonium (DPI), all added 30 min before addition of hrSerpinB3. 
Data in bar graphs are expressed as means ± SEM of three independent experiments (*p < 0.05 or **p < 0.01 
vs control values, #p < 0.05 vs related stimulus). Images from Western blot analysis or from evaluation of ROS 
generation are representative from at least three experiments performed. The cropped gels shows in this Fig. 
have been run under the same experimental conditions.
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diet than in similarly treated wild-type animals (Figs 6 and 7). Consistently, Q-PCR analysis for a set of genes 
involved in fibrogenesis demonstrated that in both the experimental models the hepatic transcripts for colla-
gen 1A1 (Col1a1), tissue inhibitor of metalloproteases type 1 (Timp1) and TGFβ1 (Tgfb1) were significantly 
enhanced in TG-SB3 (Figs 6 and 7). Among TG-SB3 mice receiving CCl4 and the MCD diet we also observed a 
significant positive correlation (r = 0.74; p = 0.04) between the individual levels of circulating SerpinB3 and those 
of liver collagen 1A1 transcripts. The mRNAs for heme-oxygenase 1 (Hmox-1) and matrix-metalloprotease type 
2 (Mmp2) were also elevated in TG-SB3 animals receiving the MCD diet, but not in those exposed to CCl4 (Figs 6 
and 7). Altogether, these data provide in vitro and in vivo evidence supporting the implication of SerpinB3 in the 
processes leading to CLD progression to fibrosis.
Discussion
SerpinB3 is virtually undetectable in normal human livers, but several studies have evidenced the presence of 
SerpinB3 in liver biopsies from patients with CLD, mostly chronic HCV infection, where it has been associated 
to CLD progression and liver carcinogenesis13–21. In fact, in CLD patients SerpinB3 up-regulation correlates with 
TGF-β1 expression and the extent of hepatic fibrosis12. Furthermore, experiments using hepatocyte-derived cell 
lines over-expressing SerpinB3 have evidenced its role in promoting TGF-β1 production, suggesting SerpinB3 
as a putative pro-fibrogenic mediator. More recently, SerpinB3 expression has been reported to be up-regulated 
by hypoxia through a HIF-2α-dependent and ROS-modulated mechanism19. This is a potentially critical issue, 
since in the last decade liver hypoxia and angiogenesis have been suggested to parallel or even drive the fibro-
genic progression of CLDs6, 25, 26, 29–31. Literature data relating SerpinB3 with advanced cirrhosis and hepato-
cellular carcinoma have also evidenced that, beside enhancing TGF-β1 expression, SerpinB3 can induce 
epithelial-mesenchymal transition (EMT) of hepatoma cancer cells, resulting in their increased invasiveness 
and proliferation12, 17, 19, 21. Indeed, in HCC patients high levels of SerpinB3 were significantly associated with 
Figure 4. SerpinB3 overexpression in TG mice and human liver specimens from HCV patients. (a) Liver 
morphology (hematoxylin/eosin staining) and immunohistochemistry (IHC) for SerpinB3 expression in the 
liver of control WT and TG mice. Original magnification as indicated. (b) Western blot analysis of SerpinB3 
protein levels performed on total liver extracts obtained from either WT and TG mice. Equal loading was 
monitored by re-blotting membranes for β-actin. The cropped gels shows in this Fig. have been run under the 
same experimental conditions. Immunohistochemistry analysis for (c) SerpinB3 and α-smooth muscle actin 
(α-SMA) or (d) for HIF2α, SerpinB3, and VEGF-A in liver specimens from HCV infected patients (METAVIR 
F4).
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early tumour recurrence and poor prognosis21. However, the involvement of EMT in liver fibrogenesis has been 
recently challenged, with most researchers suggesting a minor, if any, pro-fibrogenic role for EMT and supporting 
the concept that MFs originate mainly from activation/trans-differentiation of HSC4, 6, 8, 9, 32. These considerations 
have led us to explore the hypothesis that SerpinB3 might directly affect the behaviour of MF-like cells.
Our in vitro experiments show that hrSerpinB3 can directly act on activated HSCs by both up-regulating 
the transcription of critical genes involved in fibrogenesis and stimulating their oriented migration. In these 
settings, the capacity of the cells to readily respond to hrSerpinB suggests that SerpinB3 may exert its action 
on a receptor-mediated basis. Furthermore, at difference of other mediators involved in fibrogenesis, SerpinB3 
action on human activated HSCs seems quite selective and does not involves cell proliferation. Unfortunately, at 
present a specific receptor for SerpinB3 has not yet been characterized. Whatever might be the receptor involved, 
in human HSC/MFs SerpinB3 promotes NADPH-oxidase-dependent generation of intracellular ROS and 
ROS-related activation of JNK1/2 signalling pathways. These intracellular events have been implicated in both 
up-regulation of ECM synthesis/remodelling by MFs as well as in the induction of their oriented migration1–6. 
The latter is a relevant issue for these cells in order to align with nascent and more mature fibrotic septa. On this 
respect, it is noteworthy that the signal pathways leading to SerpinB3-induced oriented migration are identical 
to those characterized in human HSC/MFs migrating in response to chemo-attractant polypeptides (PDGF-BB, 
CCL2 and VEGF) or hypoxic conditions27, 30.
Beside the chemotactic action, the exposure of HSC/MFs or LX2 cells to hrSerpinB3 also results in 
an increased transcription of genes relevant for the fibrogenic progression of CLD along with VEGF-A, 
Angiopoietin-1 and CCL2, suggesting that SerpinB3 may combine pro-fibrogenic and pro-angiogenic activi-
ties. Of interest, the pro-fibrogenic genes stimulated “in vitro” by hrSerpinB3 are also up-regulated in response 
to chronic liver injury in transgenic mice over-expressing human SerpinB3. Accordingly, by using SerpinB3 
transgenic mice we observed that the induction of chronic liver injury by repeated exposure to CCl4, or the 
Figure 5. Parenchymal injury and inflammatory markers in SerpinB3 transgenic (SB3-TG) mice and wild 
type (WT) mice following chronic (10 weeks) CCl4 administration or 4 weeks feeding with a methionine/
choline deficient (MCD) diet. (a) Liver morphology in mice exposed to CCl4 or the MCD diet was evaluated by 
hematoxylin/eosin staining (magnification 10X). Parenchymal injury, estimated by measuring the circulating 
levels of alanine (ALT) and aspartate (AST) aminotransferases and liver expression of inflammatory markers 
TNF-α and CD11c, evaluated by quantitative real-time PCR (Q-PCR), are reported in CCl4 treated mice (b) 
and in MCD fed mice (c). Data in graphs are expressed as means ± SD (n = 6 mice for each experimental group) 
(*p < 0.01 vs the relative control mice; §p < 0.05 vs WT-mice receiving CCl4 or the MCD diet).
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development of steatohepatitis in mice fed the MCD diet leads to a massive stimulation in SerpinB3 produc-
tion by the hepatocytes and a very significant increase in ECM deposition. This later effect was associated with 
an increase in the number of α-SMA-positive cells (i.e., MF-like cells) as well as in an enhanced transcription 
of several pro-fibrogenic genes, including collagen 1A1, TGFβ1, α-SMA, PDGF-B and TIMP1 as compared to 
WT-mice. This scenario resembles that previously outlined for bleomycin-induced lung fibrosis, in which a direct 
correlation between SerpinB3 expression, TGFβ1 levels and lung fibrosis was reported24. The enhanced deposi-
tion of extracellular matrix observed in SerpinB3 transgenic mice exposed to chronic liver injury is independent 
from the extent of parenchymal injury supporting in vitro data concerning direct stimulation of MF-like cells by 
SerpinB3. Nonetheless, we have observed that hepatic damage in SerpinB3 transgenic mice associates with an 
enhanced expression of inflammatory markers. At present, it is still unclear whether SerpinB3 can directly sustain 
the activation of liver inflammatory cells but since chronic inflammation is one of the driving force for the pro-
gression of hepatic fibrosis, we cannot exclude that a pro-inflammatory action of SerpinB3 might also contribute 
to the dramatic increase in liver collagen deposition observed in our experimental settings. By contrast, we do 
not have in vitro or in vivo evidence that other non-parenchymal cells, in particular macrophages, may express 
and release SerpinB3.
A previous study has shown that SerpinB3 expression in the liver is modulated by hypoxia through 
HIF2α-dependent mechanisms19. Based on the knowledge that hypoxic conditions have a pro-fibrogenic and 
pro-angiogenic role during the progression of CLD1–6, 25, 26, 29–34, our study points on the possible implication of 
SerpinB3 among the mediators responsible for the pro-fibrogenic action of hepatic hypoxia.
In conclusion, the present study provides for the first time evidence indicating that SerpinB3 produced by liver 
parenchymal cells can contribute to the fibrogenic progression of CLDs by stimulating the responses of HSC/
MFs.
Figure 6. Liver fibrosis “in vivo” in SerpinB3 transgenic (TG) mice vs wild type (WT) mice exposed to chronic 
CCl4 administration. (a,c) Following chronic exposure to CCl4 (10 weeks) liver fibrosis was morphologically 
evaluated by Sirius red staining (a) or by immunohistochemistry for α-SMA (c). Original magnification 
as indicated. (b,d) ImageJ software analysis was performed for both Sirius red staining (b) and α-SMA 
immunohistochemistry analysis (d) to evaluate the amount of fibrosis. (e) Analysis by quantitative real-time 
PCR (Q-PCR) of SerpinB3 transcript levels of pro-fibrogenic genes in the different experimental groups. Data 
in graphs are expressed as means ± SEM (n = 6 mice for any experimental group) (*p < 0.05 vs relative control 
mice; #p < 0.05 vs WT-mice treated with CCl4).
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Materials and Methods
In vitro experiments with activated, MF-like, hepatic stellate cells or HepG2 cells. Human 
LX2 cells, a model of immortalized and activated, MF-like, human HSC, were kindly provided by Prof. Scott 
L. Friedman and were cultured in Dulbecco’s modified Eagle’s medium (Sigma Aldrich Spa, Milan, Italy), sup-
plemented with 10% fetal calf serum and 1% antibiotics. In some experiments we also used human HSC that 
were isolated from surgical wedge sections of at least three different human livers not suitable for transplanta-
tion as previously described35. These HSCs, kindly provided by Prof. Fabio Marra, were cultured as previously 
described27 and used between passages 4 and 7 when showing a phenotype of fully activated, MF-like HSCs 
(HSC/MFs), plated to obtain the desired sub-confluence level and then left for 24 hrs in serum-free Iscove’s 
medium to have cells at the lowest level of spontaneous proliferation. In in vitro experiments LX2 cells or HSC/
MFs were exposed to human recombinant SerpinB3 (hrSerpinB3, 100 ng/ml), obtained as previously described17.
Detection of intracellular generation of ROS. Detection of ROS generation in cultured cells was per-
formed by either the conversion of 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA, 1 μM) into the corre-
sponding fluorescent derivative or by combining DCFH-DA technique and flow cytometric analysis as previously 
described19, 27. More details are available in the Supplementary Material section.
Quantitative real-time PCR (Q-PCR). RNA extraction, complementary DNA synthesis, quantitative 
real-time PCR (Q-PCR) reactions were performed as previously described19, 21. mRNA levels were measured by 
Q-PCR, using the SYBR® green method as described21. More details and oligonucleotide sequences of primers 
used for Q-PCR are available in the Supplementary Material section.
Figure 7. Liver fibrosis “in vivo” in SerpinB3 transgenic (SB3-TG) mice vs wild type (WT) mice fed with MCD 
diet. (a,c) Following MCD diet (8 weeks) liver fibrosis was morphologically evaluated by Sirius red staining (a) 
or by immunohistochemistry for α-SMA (c). Original magnification as indicated. (b,d) ImageJ software analysis 
was performed for both Sirius red staining (b) and α-SMA immunohistochemistry analysis (d) to evaluate the 
amount of fibrosis. (e) Analysis by quantitative real-time PCR (Q-PCR) of SerpinB3 transcript levels of pro-
fibrogenic genes in the different experimental groups. Data in graphs are expressed as means ± SEM (n = 6 mice 
for any experimental group) (*p < 0.05 or **p < 0.01 vs relative control mice; #p < 0.05 vs WT-mice fed with 
MCD diet). Col1a1: collagen 1A1; Timp1: tissue inhibitor of metalloproteases type 1; Tgfb1: TGFβ1; Hmox-1: 
heme-oxygenase 1; Mmp2: matrix-metalloprotease type 2.
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Proliferation and Chemotaxis. Proliferation of human LX2 cells or primary HSC/MFs was evaluated by 
crystal violet proliferation assay by seeding cells in a 96-well plate at a density of 1.5 × 103 cells per well. The cells 
were incubated in serum-free medium (SFM) for 24 hrs at 100 ng/ml hrSerpinB3 concentration. At the desired 
time, the medium was removed, and the cells were washed twice with phosphate-buffered saline, fixed with 11% 
glutaraldehyde; after fixation, cells were washed with H2O bd and then stained with 0.1% (w/v) crystal violet solu-
tion for 10 min. After washing with water, the crystal violet was solubilized with 50 μl of 10% acetic acid solution, 
and absorbance was measured at 595–650 nm using a microplate reader (SpectraMAX M3; Molecular Devices, 
Sunnyvale, CA, USA). Chemotaxis of human LX2 cells or HSC/MFs was evaluated by performing the modified 
Boyden’s chamber assay as previously described27, 30.
Experimental fibrosis in SerpinB3 transgenic mice and related wild type mice. The two proto-
cols for experimental fibrosis employed in this study were performed by taking advantage of a model of C57Bl/6 
transgenic (TG) mice, fully characterized in previous studies23, 24, that overexpress human SerpinB3 in the liver 
and lungs. Full details of the experimental protocols on TG-mice and age-matched C57Bl/6 wild type (WT) 
mice, receiving either i) chronic administration of carbon tetrachloride (CCl4, Sigma-Aldrich, Milano, Italy) for 
10 weeks as described by Wang et al.36 or ii) the methionine- and choline-deficient (MCD) diet up to 8 weeks (as 
a model of NAFLD/NASH-related fibrosis)37 are described in the Supplementary Material section. Experiments 
and protocols, approved by the Animal Ethical Committee of University of Padua and by the Animal Investigation 
Committee of the Italian Ministry of Health, were performed in accordance with the Helsinki convention and 
national guidelines and regulations for animal experiments provided by Italian Ministry of Health.
Serological analysis. ALT and AST were determined in serum by laboratory routine assays. Circulating 
SerpinB3 was evaluated by enzyme-linked immunozymatic assay (SCCA-ELISA, Xeptagen, Marghera, VE, Italy) 
using biotinylated rabbit anti-human SerpinB3 antibody as previously described15.
Immunohistochemistry, Sirius Red staining and histo-morphometric analysis. Paraffin liver 
sections of cirrhotic specimens derived from patients with HCV-related liver cirrhosis (METAVIR F4) were 
employed. The use of human material conforms to the ethical guidelines of the 1975 Declaration of Helsinki and 
was approved for this study by the University of Torino Bioethical Committee. Immunostaining procedure19, 27  
and Sirius Red staining38 were as previously described, as detailed in the Supplementary Material section. 
Quantification of fibrosis in the murine liver was performed by histo-morphometric analysis using a digital cam-
era and a bright field microscope to collect images that were then analyzed by employing the ImageJ software.
Statistical analysis. The data presented are means ± SEM or SD and were obtained from at least three 
independent experiments. Luminograms and morphological images are representative of at least three experi-
ments with similar results. Statistical analysis for these experiments was performed by Student’s t-test or one way 
ANOVA with Kruskal-Wallis correction for multiple analysis. Significance was taken at p < 0.05.
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